Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 14/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114635 | 0.88 | PKM (0.75) | CD4PKMALDH1A1POLBHTT | |
| SCHEMBL13925171 | 0.84 | KMT2A (0.71) | CD4PKMALDH1A1POLBHTT | |
| SCHEMBL9693041 | 0.84 | PKM (0.66) | PKMALDH1A1POLBHTTMMP2 | |
| SCHEMBL12330052 | 0.84 | PKM (0.66) | PKMALDH1A1POLBHTTMMP2 | |
| SCHEMBL4109280 | 0.83 | CD4 (0.60) | CD4PKMALDH1A1POLBHTT | |
| SCHEMBL11605844 | 0.82 | PKM (0.63) | PKMALDH1A1POLBHTTMMP2 | |
| SCHEMBL13548367 | 0.81 | PKM (0.66) | CD4PKMALDH1A1POLBHTT | |
| SCHEMBL11773546 | 0.81 | PKM (0.61) | PKMALDH1A1POLBHTTMMP2 | |
| SCHEMBL13925187 | 0.81 | LMNA (0.65) | CD4PKMALDH1A1POLBHTT | |
| SCHEMBL13925193 | 0.80 | CD4 (0.60) | CD4PKMALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3990449-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20050171183-A1 | Indole-type inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-6890938-B2 | Indole-type inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030100588-A1 | Indole-type inhibitors of p38 kinase | SCIOS, INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100588-A1 | Indole-type inhibitors of p38 kinase | CNKSR1, MAPK1, MAP2K6 | CD4 2721/4885PKM 1425/4885ALDH1A1 3213/4885 |
| US-20050171183-A1 | Indole-type inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAP3K1 | CD4 2800/4885PKM 690/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.